General
Preferred name
TALAZOPARIB
Synonyms
BMN 673ts ()
BMN-673 ()
TALAZOPARIB TOSYLATE ()
LT-673 ()
BICALUTAMIDE ()
Talazoparib (BMN 673) ()
BMN 673 ()
TALZENNA ()
Talazoparib tosilate ()
BMN-673TS ()
P&D ID
PD010641
CAS
1207456-01-6
1373431-65-2
Tags
available
drug
probe
Approved by
FDA
EMA
First approval
2018
Drug indication
Breast cancer
Psoriatic arthritis
Drug Status
approved
investigational
Max Phase
4.0
Probe info
Probe selectivity
family-selective
Probe type
experimental probe
P&D approved
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
9
No orthogonal probes found
Similar probes
2
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY
Talazoparib is clastogenic due to its pharmacological mechanism [FDA Label]. Talazoparib does not appear to be mutagenic and no data is available on carcinogenicity. ; ; In repeat-dose toxicity studies up to 3-months duration at doses â¥0.04 mg/kg/day in rats and â¥0.01 mg/kg/day in dogs resulted in decreased organ weights, luminal cellular debris, reduced sperm, and degeneration/atrophy in the testis and epididymis [FDA Label]. These doses were equivalent to approximately 1.0 times and 0.2 times normal human exposure. Follicular atresia of the ovary was observed in rats at doses â¥1 mg/kg/day, equivalent to 9.5 times normal human exposure. While no fertility data exists these results suggest a potential for reduced fertility due to talazoparib exposure.
MOA
Inhibitor
(Chemical Probes.org)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
10
Organisms
0
Compound Sets
24
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Chemical Probes.org
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
High-quality chemical probes
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
Welcome Trust Cancer Drugs
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
44
Molecular Weight
380.12
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
5
Aromatic Ring Count
4
cLogP
2.63
TPSA
88.49
Fraction CSP3
0.16
Chiral centers
2.0
Largest ring
6.0
QED
0.56
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Genome integrity
Cell Cycle/DNA Damage
Epigenetics
Target
PARP1, PARP2
PARP2
PARP
Member status
member
MOA
Inhibitor of PARP1 and PARP2
PARP inhibitor
Indication
breast cancer
Therapeutic Class
Poly (ADP-ribose) polymerase (PARP) inhibitor
Target class
Other post-translational modification, Other post-translational modification
Target subclass
PARP, PARP
Source data
